Lexaria Bioscience Begins GLP-1 Study, Files New Patents

Lexaria Bioscience Corp. (Nasdaq: LEXX) has announced that its Animal Study #1 (GLP-1-A26-1) is now underway, evaluating novel formulations using DehydraTECH-semaglutide (DHT-sema) and DehydraTECH-CBD (DHT-CBD) compositions. The study aims to explore enhanced performance and stake new intellectual property claims, particularly focusing on alternatives to SNAC (salcaprozate sodium), used by Novo Nordisk in oral Rybelsus and Wegovy. Dosing began June 10, 2026, with results expected by early September. Lexaria has already filed three new patent applications for technological improvements in this area, signaling a push to establish proprietary IP in the competitive GLP-1 sector. The study uses 11 arms in Sprague-Dawley rats with pharmacokinetic measurements over 8-24 hours, including brain tissue absorption, leveraging DehydraTECH's previously demonstrated superior absorption of active ingredients into brain tissue. This is crucial as GLP-1 drug performance is increasingly linked to brain neurochemistry. Reference arms with existing DHT-sema and DHT-CBD compositions will serve as baselines. The study is fully funded from existing resources.

In addition, Lexaria received its first Australian patent grant (#2023302884) for Family #21, covering pharmaceutical compositions and methods for treating hypertension. This adds to seven patents in this family across the US, Europe, and Japan, with a term until April 2043. Lexaria's DehydraTECH platform aims to improve oral drug delivery, enhancing bio-absorption, reducing side-effects, and crossing the blood-brain barrier. The company holds 66 granted patents worldwide and operates a licensed in-house research laboratory. This development underscores Lexaria's commitment to innovation in drug delivery, potentially offering alternatives to existing SNAC-based formulations and expanding its IP portfolio in high-demand therapeutic areas like GLP-1 and hypertension.